SCHEMBL10175202

SCHEMBL10175202

CCc1ccnc2cc(OC)ccc12

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 3/20 0.60
ADRA1D P25100 3/20 0.60
ADRA1A P35348 3/20 0.60
ADRA1B P35368 3/20 0.60
FERMT2 Q96AC1 1/20 0.55
MTNR1A P48039 3/20 0.51
MTNR1B P49286 3/20 0.51
TLR8 Q9NR97 1/20 0.49
CYP1A2 P05177 1/20 0.49
GAK O14976 1/20 0.49
RIPK2 O43353 1/20 0.49
COQ8A Q8NI60 1/20 0.49
NLK Q9UBE8 1/20 0.49
LMNA P02545 1/20 0.49
ENPP3 O14638 1/20 0.48
ENPP1 P22413 1/20 0.48
ROCK2 O75116 1/20 0.48
KDM4E B2RXH2 2/20 0.48
MAPK1 P28482 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4081621 0.88 MTNR1A (0.64) HTR1AADRA1DADRA1AADRA1BMTNR1A
SCHEMBL24010334 0.85 HTR1A (0.59) HTR1AADRA1DADRA1AADRA1BFERMT2
SCHEMBL30682081 0.85 HTR1A (0.59) HTR1AADRA1DADRA1AADRA1BFERMT2
SCHEMBL29161070 0.83 HTR1A (0.55) HTR1AADRA1DADRA1AADRA1BFERMT2
SCHEMBL7105353 0.82 HTR1A (0.56) HTR1AADRA1DADRA1AADRA1BFERMT2
SCHEMBL7156011 0.82 HTR1A (0.56) HTR1AADRA1DADRA1AADRA1BFERMT2
SCHEMBL24010540 0.82 HTR1A (0.56) HTR1AADRA1DADRA1AADRA1BFERMT2
SCHEMBL7034663 0.82 HTR1A (0.52) HTR1AADRA1DADRA1AADRA1BFERMT2
SCHEMBL27663665 0.81 HTR1A (0.58) HTR1AADRA1DADRA1AADRA1BFERMT2
SCHEMBL10240607 0.81 HTR1A (0.51) HTR1AADRA1DADRA1AADRA1BFERMT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170143731-A1 NOVEL HETEROCYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS ZENITH EPIGENETICS LTD. 2017-05-25 US disclosed
US-8163693-B2 Urea-containing peptides as inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. (US) 2012-04-24 US disclosed
US-20110070168-A1 MACROCYCLIC PEPTIDES AS INHIBITORS OF VIRAL REPLICATION ACHILLION PHARMACEUTICALS, INC. (US) 2011-03-24 US disclosed
US-7906619-B2 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. (US) 2011-03-15 US disclosed
US-7745444-B2 Inhibitors of serine proteases, particularly HCV NS3-NS4A protease VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-06-29 US disclosed
US-20100124545-A1 CYCLIC CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF AS OF HEPATITIS C VIRUS ACHILLION PHARMACEUTICALS, INC. (US) 2010-05-20 US disclosed
US-20090082261-A1 UREA-CONTAINING PEPTIDES AS INHIBITORS OF VIRAL REPLICATION ACHILLION PHARMACEUTICALS, INC. (US) 2009-03-26 US disclosed
US-20090048297-A1 4-AMINO-4-OXOBUTANOYL PEPTIDES AS INHIBITORS OF VIRAL REPLICATION ACHILLION PHARMACEUTICALS (US) 2009-02-19 US disclosed
US-20080311079-A1 Inhibitors of serine proteases, particularly HCV NS3-NS4A protease VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-12-18 US disclosed
US-7378422-B2 Inhibitors of serine proteases, particularly HCV NS3-NS4A protease VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-05-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110070168-A1 MACROCYCLIC PEPTIDES AS INHIBITORS OF VIRAL REPLICATION VIP, ZC3HAV1, ZC3HAV1L HTR1A 4326/4885ADRA1D 3418/4885ADRA1A 3939/4885
US-20090082261-A1 UREA-CONTAINING PEPTIDES AS INHIBITORS OF VIRAL REPLICATION VIP, SLC14A1, RPL35 HTR1A 4694/4885ADRA1D 4159/4885ADRA1A 4530/4885
US-20170143731-A1 NOVEL HETEROCYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS BRD4, BRDT, BRD3 HTR1A 3672/4885ADRA1D 3855/4885ADRA1A 4254/4885
US-20090048297-A1 4-AMINO-4-OXOBUTANOYL PEPTIDES AS INHIBITORS OF VIRAL REPLICATION VIP, ZC3HAV1, CCL5 HTR1A 4202/4885ADRA1D 2707/4885ADRA1A 3212/4885
US-20080311079-A1 Inhibitors of serine proteases, particularly HCV NS3-NS4A protease SERPINB1, PRSS1, SPINT2 HTR1A 2529/4885ADRA1D 4625/4885ADRA1A 4554/4885
US-20100124545-A1 CYCLIC CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF AS OF HEPATITIS C VIRUS CPS1, CCKAR, C1R HTR1A 2173/4885ADRA1D 3749/4885ADRA1A 3522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.